Silverback Total Assets from 2010 to 2025

SPRY Stock

14.29 1.27 9.75%

Silverback Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 136 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

268.2 M

Current Value

136 M

Quarterly Volatility

98.8 M

Credit Downgrade

Yuan Drop

Covid

Check Silverback Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silverback Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.4 K, Other Operating Expenses of 81.6 M or Research Development of 20.8 M, as well as many indicators such as Price To Sales Ratio of 16.4 K, Dividend Yield of 0.0 or PTB Ratio of 2.14. Silverback financial statements analysis is a perfect complement when working with Silverback Therapeutics Valuation or Volatility modules.

Check out the analysis of Silverback Therapeutics Correlation against competitors.

For more information on how to buy Silverback Stock please use our How to Invest in Silverback Therapeutics guide.

Latest Silverback Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Silverback Therapeutics over the last few years. Total assets refers to the total amount of Silverback Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Silverback Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Silverback Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Silverback Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 233.19 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Silverback Total Assets Regression Statistics

	Arithmetic Mean	72,693,704
	Geometric Mean	34,146,354
	Coefficient Of Variation	135.88
	Mean Deviation	78,500,181
	Median	15,647,000
	Standard Deviation	98,778,921
	Sample Variance	9757.3T
	Range	265.8M
	R-Value	0.73
	Mean Square Error	4939.2T
	R-Squared	0.53
	Significance	0
	Slope	15,069,539
	Total Sum of Squares	146359.1T

Silverback Total Assets History

	2025	136 M
	2024	268.2 M
	2023	233.2 M
	2022	281.4 M
	2021	61.4 M
	2020	26.4 M

Other Fundumenentals of Silverback Therapeutics

Intangibles To Total Assets

Silverback Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Capital Surpluse	Intangible Assets
Total Assets		0.93	-0.87	-0.72	-0.79	-0.39	1.0	-0.84	0.92	-0.92	-0.89	0.87	0.93	0.9	-0.93	1.0	-0.93	0.64	-0.4	-0.4
Total Stockholder Equity	0.93		-0.79	-0.82	-0.78	-0.57	0.93	-0.81	1.0	-0.92	-0.84	0.88	1.0	0.82	-1.0	0.95	-1.0	0.56	-0.65	-0.65
Net Debt	-0.87	-0.79		0.39	0.66	0.17	-0.87	0.78	-0.75	0.8	0.78	-0.72	-0.79	-0.74	0.77	-0.86	0.77	-0.64	0.25	0.25
Retained Earnings	-0.72	-0.82	0.39		0.52	0.68	-0.72	0.48	-0.84	0.75	0.65	-0.72	-0.82	-0.65	0.84	-0.76	0.84	-0.38	0.57	0.57
Accounts Payable	-0.79	-0.78	0.66	0.52		0.09	-0.8	0.98	-0.81	0.88	0.86	-0.55	-0.8	-0.84	0.79	-0.79	0.79	-0.74	0.59	0.59
Total Liab	-0.39	-0.57	0.17	0.68	0.09		-0.38	0.07	-0.56	0.23	0.05	-0.76	-0.56	-0.08	0.6	-0.43	0.6	0.33	0.36	0.36
Total Current Assets	1.0	0.93	-0.87	-0.72	-0.8	-0.38		-0.85	0.92	-0.93	-0.89	0.87	0.93	0.9	-0.93	1.0	-0.93	0.65	-0.4	-0.4
Short Term Debt	-0.84	-0.81	0.78	0.48	0.98	0.07	-0.85		-0.82	0.9	0.89	-0.59	-0.82	-0.87	0.8	-0.84	0.8	-0.77	0.52	0.52
Net Tangible Assets	0.92	1.0	-0.75	-0.84	-0.81	-0.56	0.92	-0.82		-0.93	-0.85	0.86	1.0	0.83	-0.99	0.95	-0.99	0.58	-0.68	-0.68
Current Deferred Revenue	-0.92	-0.92	0.8	0.75	0.88	0.23	-0.93	0.9	-0.93		0.98	-0.68	-0.93	-0.95	0.91	-0.94	0.91	-0.83	0.6	0.6
Long Term Debt	-0.89	-0.84	0.78	0.65	0.86	0.05	-0.89	0.89	-0.85	0.98		-0.57	-0.84	-0.98	0.82	-0.89	0.82	-0.91	0.54	0.54
Net Receivables	0.87	0.88	-0.72	-0.72	-0.55	-0.76	0.87	-0.59	0.86	-0.68	-0.57		0.88	0.6	-0.9	0.88	-0.9	0.2	-0.35	-0.35
Net Invested Capital	0.93	1.0	-0.79	-0.82	-0.8	-0.56	0.93	-0.82	1.0	-0.93	-0.84	0.88		0.82	-1.0	0.96	-1.0	0.57	-0.65	-0.65
Short Long Term Debt	0.9	0.82	-0.74	-0.65	-0.84	-0.08	0.9	-0.87	0.83	-0.95	-0.98	0.6	0.82		-0.8	0.9	-0.8	0.88	-0.5	-0.5
Capital Stock	-0.93	-1.0	0.77	0.84	0.79	0.6	-0.93	0.8	-0.99	0.91	0.82	-0.9	-1.0	-0.8		-0.96	1.0	-0.53	0.62	0.62
Net Working Capital	1.0	0.95	-0.86	-0.76	-0.79	-0.43	1.0	-0.84	0.95	-0.94	-0.89	0.88	0.96	0.9	-0.96		-0.96	0.64	-0.45	-0.45
Common Stock	-0.93	-1.0	0.77	0.84	0.79	0.6	-0.93	0.8	-0.99	0.91	0.82	-0.9	-1.0	-0.8	1.0	-0.96		-0.53	0.62	0.62
Property Plant Equipment	0.64	0.56	-0.64	-0.38	-0.74	0.33	0.65	-0.77	0.58	-0.83	-0.91	0.2	0.57	0.88	-0.53	0.64	-0.53		-0.42	-0.42
Capital Surpluse	-0.4	-0.65	0.25	0.57	0.59	0.36	-0.4	0.52	-0.68	0.6	0.54	-0.35	-0.65	-0.5	0.62	-0.45	0.62	-0.42		1.0
Intangible Assets	-0.4	-0.65	0.25	0.57	0.59	0.36	-0.4	0.52	-0.68	0.6	0.54	-0.35	-0.65	-0.5	0.62	-0.45	0.62	-0.42	1.0

Click cells to compare fundamentals

About Silverback Therapeutics Financial Statements

Silverback Therapeutics investors use historical fundamental indicators, such as Silverback Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Silverback Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	268.2 M	136 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation

Additional Tools for Silverback Stock Analysis

When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC